Skip to main content
Log in

Sequential Versus Combined Treatment of Human Breast Cancer Cells with Antiestrogens and the Vitamin D Analogue EB1089 and Evaluation of Predictive Markers for Vitamin D Treatment

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Development of resistance to antihormonal therapy is a major problem in the treatment of breast cancer patients. Metastatic tumors, which progress after a period of response to treatment, often respond to second line endocrine treatment, but eventually develop estrogen independent growth. Vitamin D analogues are promising new drugs, using alternative mechanisms to inhibit growth of breast cancer cells. The sensitivity to antiestrogens and vitamin D analogues has been proposed to be inverse, indicating that the sensitivity to vitamin D analogues might increase after development of antiestrogen resistance and vice versa. In this study, the inverse sensitivity between antiestrogens and the vitamin D analogue EB1089 was examined in antiestrogen and vitamin D resistant breast cancer cell lines. The majority of the investigated antiestrogen resistant cell lines had increased sensitivity to treatment with the vitamin D analogue EB1089. In addition, growth of a vitamin D resistant cell line was more inhibited by the pure antiestrogen ICI 182,780 than the growth of the parental cells, indicating that the compounds may be used sequentially. An association between the expression level of the vitamin D receptor (VDR) and EB1089 sensitivity was observed, suggesting that VDR is a possible predictive marker for response to vitamin D treatment. Valuation of Bcl-2 gene expression may be useful in combination with VDR to predict the outcome of treatment with EB1089. Furthermore, we observed a synergistic growth inhibition and an abrogated development of resistance upon combined treatment with ICI 182,780 and EB1089. Therefore, antiestrogens and vitamin D analogues may also be used as combined treatment for breast cancer patients in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society: Cancer facts and figures, www.cancer.org, 2002

  2. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606, 2001

    Google Scholar 

  3. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758–3767, 2000

    Google Scholar 

  4. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1: 16–19, 1985

    Google Scholar 

  5. Dowsett M, Ellis MJ: Role of biologic markers in patient selection and application to disease prevention. Am J Clin Oncol 26: S34–S39, 2003

    Google Scholar 

  6. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in Antiestrogen and vitamin D treatment of human breast cancer cell lines 63 tamoxifen-resistant human breast cancer. Cancer Res 55: 3331–3338, 1995

    Google Scholar 

  7. MadsenMW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE: Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585–589, 1997

    Google Scholar 

  8. Osborne CK, Yochmowitz MG, Knight III WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1980

    Google Scholar 

  9. Blichert-Toft M, Ejlertsen B, Mouridsen H, Overgaard M: Breast cancer. Ugeskr Laeger 164: 3023–3026, 2002

    Google Scholar 

  10. Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL: A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 86: 680–685, 2002

    Google Scholar 

  11. Hansen CM, Hamberg KJ, Binderup E, Binderup L: Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr Pharm Des 6: 803–828, 2000

    Google Scholar 

  12. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC: EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44: 2273–2280, 1992

    Google Scholar 

  13. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT, Combes RC: Topical calcipotriol treatment in advanced breast cancer. Lancet 337: 701–702, 1991

    Google Scholar 

  14. Nolan E, Donepudi M, VanWeelden K, Flanagan L, Welsh J: Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells. Mol Cell Biochem 188: 13–20, 1998

    Google Scholar 

  15. Larsen SS, Heiberg I, Lykkesfeldt AE: Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br J Cancer 84: 686–690, 2001

    Google Scholar 

  16. Hansen CM, Rohde L, Madsen MW, Hansen D, Colston KW, Pirianov G, Holm PK, Binderup L: MCF-7/VD(R): a new vitamin D resistant cell line. J Cell Biochem 82: 422–436, 2001

    Google Scholar 

  17. Jensen SS, Madsen MW, Lukas J, Bartek J, Binderup L: Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with vitamin D receptor protein induction. J Steroid Biochem Mol Biol 81: 123–133, 2002

    Google Scholar 

  18. Mathiasen IS, Lademann U, Jaattela M: Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59: 4848–4856, 1999

    Google Scholar 

  19. Briand P, Lykkesfeldt AE: Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res 44: 1114–1119, 1984

    Google Scholar 

  20. Lykkesfeldt AE, Briand P: Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer 53: 29–35, 1986

    Google Scholar 

  21. Lykkesfeldt AE, Larsen SS, Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61: 529–534, 1995

    Google Scholar 

  22. Lundholt BK, Briand P, Lykkesfeldt AE: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 67: 199–214, 2001

    Google Scholar 

  23. Slinker BK: The statistics of synergism. JMol Cell Cardiol 30: 723–731, 1998

    Google Scholar 

  24. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54: 408–414, 1994

    Google Scholar 

  25. Fisher B, Fisher ER, Redmond C, Brown A: Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res Treat 7: 147–160, 1986

    Google Scholar 

  26. McGuire WL: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428–433, 1978

    Google Scholar 

  27. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C, Safe S: Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274: 32099–32107, 1999

    Google Scholar 

  28. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J: Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42: 31–41, 1997

    Google Scholar 

  29. Vink-van Wijngaarden T, Pols HA, Buurman CJ, van den Bemd GJ, Dorssers LC, Birkenhager JC, van Leeuwen JP: Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54: 5711–5717, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christensen, G., Jepsen, J., Fog, C. et al. Sequential Versus Combined Treatment of Human Breast Cancer Cells with Antiestrogens and the Vitamin D Analogue EB1089 and Evaluation of Predictive Markers for Vitamin D Treatment. Breast Cancer Res Treat 85, 53–63 (2004). https://doi.org/10.1023/B:BREA.0000021047.37869.95

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000021047.37869.95

Navigation